• Hodgkin’s Lymphoma:
    • 1st line treatment or previously untreated Stage III or IV HL in combination with doxorubicin, vinblastine and dacarbazine (AVD):
      • IV 1.2mg/kg every 2 weeks
      • Not to exceed 120mg/dose
      • Continue until a maximum of 12 doses, disease progression or untolerable toxicity
    • Consolidation treatment:
      • IV 1.8mg/kg every 3 weeks
      • Max: 180mg/dose
      • For patients with high risk of relapse or progression
      • Give up to 16 cycles
    • Relapsed treatment after failure of post-autologous hematopoietic stem cell transplantation (auto-HSCT) or after failure of at least 2 prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates:
      • IV 1.8mg/kg every 3 weeks
      • Not to exceed 180mg/dose
      • Continue until disease progression or untolerable toxicity
  • Systemic anaplastic large cell lymphoma
    • 1st line treatment:
      • IV 1.8 mg/kg every 3 weeks for 6-8 doses
      • Not to exceed 180mg/dose
      • Part of a multi-drug chemo regimen
      • Give up to 6-8 cycles
      • Give with primary prophylaxis G-CSF starting cycle 1
    • Relapsed/refractory disease after failure of at least 1 prior multiagent chemotherapy regimen:
      • IV 1.8 mg/kg every 3 weeks
      • Continue until disease progression or untolerable toxicity
  • Previously untreated CD30-expressing peripheral T-cell lymphoma:
    • IV 1.8 mg/kg every 3 weeks for 6-8 doses
    • Max: 180mg/dose
    • Used in combination with cyclophosphamide, doxorubicin and prednisone (CHP)
  • Primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30 expressing mycosis fungoides (MF) in patients who have received prior systemic therapy:
    • IV 1.8 mg/kg every 3 weeks
    • Max: 180mg/dose
    • Continue until disease progression, untolerable toxicity or a max of 16 cycles

Injection: 50mg

  • Infuse over 30 minutes
  • Do not administer as an IV push or bolus
  • Reconstituted with 10.5 mL sterile water for injection to yield 5mg/mL
  • Any drug left in vial should be discarded
  • Reconstituted solution can be diluted in at least 100 mL of 0.9% NaCl, D5W or LR (final concentration: 0.4-1.8 mg/mL)
  • Unopened vials are refrigerated at 2-8°C in original carton to protect from light
  • Diluted solutions or reconstituted vials are refrigerated at 2-8°C for up to 24 hours

Antimicrotuble agent anticancer

It binds CD30-expressing cells forming internalized complex which releases monomethyl auristatin E (MMAE) intracellularly. MMAE binds to microtubules, inhibiting mitosis and inducing apoptosis (antibody-drug conjugate).

  • Neutropenia
  • Peripheral neuropathy
  • Anemia
  • Fatigue
  • Nausea
  • Thrombocytopenia
  • Diarrhea
  • URI
  • Fever
  • Stomatitis
  • Cough
  • Vomiting
  • Pruritus
  • Arthralgia
  • Dyspnea
  • Myalgia
  • Rash
  • Infusion reaction
  • Decreased appetite
  • Constipation
  • Abdominal pain
  • Headache
  • Increased ALT
  • Rigors
  • Weight loss
  • Alopecia
  • Muscle spasms
  • Insomnia
  • Dizziness
  • Back pain
  • Lymphadenopathy
  • Peripheral edema
  • Pain
  • Extremity pain
  • Night sweats
  • Anxiety
  • Oropharyngeal pain
  • Hyperglycemia
  • Hypersensitivity to components
  • Breastfeeding
  • CrCl <30
  • Hepatic impairment

WARNING:

Progressive Multifocal Leukoencephalopathy; John Cunningham (JC) virus infection resulting in PML and death can occur

  • Bleomycin
  • Live bacterial vaccines

                          Drug Status

Availability Prescription only
Pregnancy Contraindicated
Breastfeeding Contraindicated
Schedule Not controlled
BRAND NAME STRENGTH FORMULATION PACK SIZE MANUFACTURER DISTRIBUTOR
Adcetris 50mg Injection 1’s Takeda Pharma Phillips Therapeutics